Data da publicação:
For three consecutive mornings in Brazil, or three nights on the other side of the world, in China, the CAS-Fiocruz webinar on Infectous Diseases brought together researchers from the Foundation and the Chinese Academy of Sciences to exchange information on topics such as COVID-19, vaccines, zika, dengue, and other diseases common to both sides of the globe. The webinar took place on December 14th, 15th, and 16th.
Article
Data da publicação:
As with other COVID-19 immunizers, a booster dose of AstraZeneca vaccine is also required after the complete vaccination schedule. This is indicated by a new study involving Brazil and Scotland, and published in the scientific journal The Lancet on Monday (12/20). The research, of which Fiocruz is part, shows the decrease in vaccine protection over time and in face of the new variants’ emergence.
Article
Data da publicação:
The ties between Fiocruz and the United States Consulate in Rio de Janeiro should become closer next year. On 12/16, the consul Jacqueline Ward and the president of Fiocruz, Nísia Trindade Lima, met at the Official Residence.
Article
Data da publicação:
Continuing an institutional movement to promote science through the dissemination of actions, research, events and courses in other languages, Fiocruz has just incorporated two new courses to the Global Health Training Centre. This time they were "What is Open Science?" and "Open Access", which were translated from Portuguese into English and Spanish.
Article
Data da publicação:
When the World Health Organization (WHO) decided to classify the Omicron strain of the new coronavirus as a variant of concern, it took into account the recommendations of a group of specialists. The so-called Technical Advisory Group on Sars-CoV-2 Evolution (TAG-VE) is a select group of scientists that includes a Brazilian virologist in its line-up: Brazilian researcher Marilda Siqueira, chief of the Laboratory of Measles and Respiratory Viruses of the Oswaldo Cruz Institute (IOC/Fiocruz).
Article
Data da publicação:
A project resulting from a partnership between the Ministry of Health, Fiocruz, Lacen-PR, and the Federal University of São Paulo (Unifesp) was one of those selected by the U.S. Centers for Disease Control and Prevention (CDC) for funding, as part of the creation of two global networks aimed at fighting antimicrobial resistance.
Article
Data da publicação:
The first edition of the bulletin on the COVID-19 vaccines' effectiveness in the Brazilian population, from Fiocruz's Vigivac project, was published on Thursday (12/9). The report, which presents analyses of the four vaccines administered in Brazil from January to October 2021, points out that all of them confer a great reduction in the risk of infection, hospitalizations, and death from COVID-19. Considering serious outcomes (hospitalization or death) in individuals aged 20-80 years, protection ranged from 83% to 99% for all immunizers.
Article
Data da publicação:
In a pioneering initiative, the Foundation inaugurates this Monday (13/12), COVID-19 Biobank (BC19-Fiocruz). Located in Rio de Janeiro, at Expansão campus, BC19-Fiocruz will enable the design and conduct of research, technological development and clinical trials related to COVID-19, regardless of the geographic location of human biological material and viruses.
Article
Data da publicação:
A research published today by The Lancet - one of the most prestigious scientific journals focused on the medical field in the world - brought together experts to explain how the economic downturn will affect for years and will be worse in developing countries. Without a consensus for preventive action, families and communities will be disproportionately affected. In the long run, inequalities in health, physical and socioeconomic well-being will widen worldwide.
Article
Data da publicação:
Designated by the United Nations, December 12th is celebrated every year as International Universal Health Coverage Day. The theme this year is Leave no one’s health behind: Invest in Health Systems for All - an issue that gained even more significance as the COVID-19 pandemic rolled on. This year’s campaign will feature a video showing people from all over the world who have shown leadership and vision in this matter, the so-called “Champions”.
Article
Data da publicação:
Fifteen years after visiting Fiocruz as a tourist, Pietro Lazzeri returned to the Foundation on Tuesday (12/07), this time as Switzerland ambassador. In office for six months, he met with Fiocruz members at the Fiocruz Global Health Center (CRIS/Fiocruz), where he proposed to expand technical and scientific cooperation. He also visited Bio-Manguinhos, where he found out that some of the machines used in the production of the COVID-19 vaccine came from his country.
Article
Data da publicação:
For one week Fiocruz will be at Expo Dubai. Starting on December 28th, visitors will be able to learn a little more about the Foundation's work and even take a virtual tour of Campus Manguinhos at the Brazil Pavilion. The World Expo takes place every five years and brings themes such as technology and sustainability. It began on October 1st, surrounded by care so that visitors can have interactive participation, but without crowds.
Article
Data da publicação:
O Complexo Industrial de Biotecnologia em Saúde (Cibs) do Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos/Fiocruz) teve homologado (30/12) o vencedor da licitação para a sua construção, no campus de Santa Cruz, na Zona Oeste do Rio de Janeiro. O resultado foi publicado no Diário Oficial da União (DOU) e a empresa vencedora foi o Consórcio do Empreendimento NCPFI RJ.
Article
Data da publicação:
The Oswaldo Cruz Foundation, by means of the Fio-Schisto, the Translational Research Program in Schistosomiasis, informs that researcher Otávio Pieri, of the Oswaldo Cruz Institute (IOC), was invited to become part of the World Health Organization (WHO) group on schistosomiasis and helminth diseases transmitted through the soil (geo helminth diseases). Fio-Schisto is bound to the Vice-Presidency of Biological Research and Collections.
Article
Data da publicação:
The search for a coordinated solution to a common problem brought together representatives from Brazil, Argentina, Paraguay, Uruguay, and Bolivia this Tuesday (9/11) in the auditorium of the Immunobiological Technology Institute (Bio-Manguinhos). Organized by the Presidency Pro Tempore of Brazil in Mercosur, the Technical Seminar on Access to COVID-19 Vaccines: National Strategies and Possibilities of Expansion of the Regional Productive Capacity brought the sharing of experiences and challenges.
Article
Data da publicação:
Last Thursday (25 November) the Oswaldo Cruz Foundation, by means of its Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz), submitted to the Brazilian Health Regulatory Agency (Anvisa) a request of post-registration alteration of its COVID-19 vaccine (recombinant), asking to include the Institute as the manufacturing unit of the Active Pharmaceutical Ingredient (API).
Article
Data da publicação:
In 2018, the king of the Yoruba people, Ooni of Ife, Oba Adeyeye Enitan Babatunde Ogunwus, visited Fiocruz and introduced the idea of a partnership in the field of traditional medicine and integrative health practices. Because of the COVID-19 pandemic, the conversation was stalled, but it was resumed this Wednesday (November 24th) with a visit of a delegation from the Palace of Ife to the Foundation.
Article
Data da publicação:
Severe cases of COVID-19 are related to the ageing of the immune system and to acute immunodeficiency. It is what the new study led by the Oswaldo Cruz Institute (IOC/Fiocruz) and by the Federal University of Rio de Janeiro (UFRJ) shows, published in the academic journal Journal of Infectious Diseases.
Article
Data da publicação:
“One mistake, one correction”: according to Carlos Morel, a researcher from the Brazilian state of Pernambuco, former Fiocruz president and current coordinator of the Center for Technological Development in Health (CDTS), this is how the world works.
Article
Data da publicação:
The first dose protects, but immunization requires a second dose and varies according to the age group and the time interval between doses. These are some conclusions of the pre-publication study that evaluated the effectiveness of the first dose of the AstraZeneca/Fiocruz vaccine against symptomatic cases of COVID-19 in the population of Complexo da Maré, in Rio de Janeiro (RJ). A 42.4% protection against symptomatic cases was estimated 21 days after the first dose of the vaccine.
Article
Data da publicação:
With two actions this week, Fiocruz became even more engaged in the fight against Hansen's, a neglected disease that had its situation aggravated during the COVID-19 pandemic. On Wednesday (11/17), the Foundation signed a Cooperation Agreement for joining the global campaign Don't Forget Hansen's Disease, with the state government and other partners, in addition to lighting the castle with purple at night as one of the actions to raise awareness.
Article
Data da publicação:
Sociologist and president of Fiocruz, Nísia Trindade Lima was appointed for The World Academy of Sciences for the advancement of science in developing countries (TWAS). The appointment was in the Academy’s General Meeting, on November 1st, as part of its 15th general conference.
Nísia is one of the 20 women who were appointed, in a total of 58 new members (Photo: Reproduction)
Article
Data da publicação:
There are a lot of statements, and a lot of commitments as well, but there is a lack of distinction of responsibilities and of the obligation in fulfilling the goals set, which hinders the operation of the G20. That is what the participants in the latest Advanced Seminar of the Fiocruz Global Health Center (CRIS/Fiocruz) point out. The G-20 Webinar: What we should expect from the richest people in the world in global and planetary health? analyzed the conclusions of the summit of the 19 countries that have the world’s main economies and the European Union.
Article
Data da publicação:
In another huge step to the internationalization of education, Fiocruz updated the ordinance that regulates the dual-degree stricto sensu graduation program regime with foreign higher education institutions regarded as of strategic relevance for the Foundation, no. 508, of 2021. The initiative allows students to get dual-degrees or titles in master's and doctorate's degrees. With this regime, when finishing the program, the student receives a diploma from a foreign institution that is part of the cooperation, along with a Fiocruz diploma.
Article
Data da publicação:
Last Thursday (28 October) Fiocruz signed, during a ceremony that took place at the headquarters of AstraZeneca, in Cambridge, United Kingdom, a joint declaration of commitment for the acquisition of Active Pharmaceutical Ingredient (API) with the goal of producing 60 million doses of the COVID-19 vaccine (recombinant) in order to make up the deliveries of the Foundation for 2022. The commitment signed by the institutions aims to guarantee wide availability of vaccine doses for the first semester.
Article
Data da publicação:
A new study published in Nature Communications last Thursday (28/11) shows that two doses of the AstraZeneca vaccine, produced in Brazil by Fiocruz, provide high protection against the Gamma variant in people above 60 years old. Based on São Paulo, the research shows that the second dose increases protection against death by about 30% when compared to the first dose, reaching an effectivity of 93.6%.
Article
Data da publicação:
Ten years after its signing, the Rio Political Declaration on Social Determinants of Health is more relevant than ever, as shown by the impacts of the COVID-19 pandemic in the world.
Article
Data da publicação:
The team of the Viral Vaccines Laboratory of the National Institute for Quality Control in Health (INCQS/Fiocruz), which works with immunobiological drugs against rabies (LVV-Raiva), is participating in the second phase of an international study to replace potency assays in anti-rabies vaccines, traditionally made using mice for over 50 years.
Article
Data da publicação:
Production of the Fiocruz Active Pharmaceutical Ingredient (API) for COVID-19 vaccines is ongoing and is now moving on to a new and important phase of the process. Two pre-validation batches of the product manufactured by Fiocruz have been approved in all in-house quality tests and are now on their way to an external quality control at USA laboratories. At these labs, the samples will go through a complex testing process that involves 14 tests in addition to those carried out in Brazil, the longest of which takes 56 days to complete.
Article